November 6, 2026

The Honorable Lisa Blunt Rochester
United States Senate
513 Hart Senate Office Building
Washington, D.C. 20510

Dear Senator Blunt Rochester:

Thank you for your recent letter inquiring about the specific circumstances related to Philadelphia Eagles quarterback Jalen Hurts' reported diagnosis of deep vein thrombosis (DVT) and bilateral pulmonary emboli (PE), as well as the National Football League's approach more generally to the detection, treatment, and management of blood clots. I sincerely appreciate how deeply personal this issue is to you and admire the leadership role that you've taken in the aftermath of your late husband's tragic passing to raise awareness and implement policies addressing DVT/PE and other serious public health challenges.

The League's highest priority is the health and safety of players. We work closely, collaboratively, and continuously with our clubs, the NFL Players Association, leading medical experts, institutions, and advisors to drive progress in the prevention, diagnosis and treatment of injuries and to provide the highest standard of medical care to every player, on and off the field.

With respect to the circumstances of Mr. Hurts' diagnosis, as you may know, the NFL and the NFL Players Association have agreed to conduct a joint review of the circumstances related to his injury. As outlined by the league and NFLPA's Collective Bargaining Agreement, mutually agreed-upon independent medical experts will review the matter and share their conclusions and recommendations with both parties. We look forward to sharing more information with you once the joint review is completed. As has been publicly reported, Jalen was placed on the injured reserve list and remains under the treatment and close supervision of medical professionals.

As a general matter, each club's medical staff evaluates and treats each individual player, on a case-by-case basis, including in cases of a suspected or confirmed blood clot. The League and Players Association also have several medical committees that review and monitor player injury data closely. For at least the past decade, the NFL has tracked clotting disorders among players every season through a subcommittee of its General Medical Committee, and this information is shared with the NFLPA. Following the ongoing joint review, the League and NFLPA will consider appropriate next steps, including whether this case points to a need for additional league-wide guidance.

Thank you again for your inquiry, and your leadership. We welcome the opportunity to provide additional information, and find ways to support your efforts around raising awareness and improving outcomes related to blood clot disorders.

Sincerely,



Jeff Miller
Executive Vice President,
Communications, Public Affairs and Health Policy